Roflumilast improves FEV1 in COPD

By  |  September 4, 2009 | 

Two recent randomized trials support the use of roflumilast, a phosphodiesterase-4 inhibitor, in moderate to severe COPD. The first randomized patients on salmeterol or tiotropium to roflumilast or placebo for 24 weeks, and found a mean increase in FEV1 of 49cc (in the salmeterol group) and 80cc (in the tiotropium group) (abstract). The second study randomized severe COPD to roflumilast or placebo for a year, with a mean increase in FEV1 of 48cc. The roflumilast patients also had a 17% reduction in number of moderate to severe exacerbations (abstract). Roflumilast may become a standard addition to regimens in moderate and severe COPD.

Leave A Comment

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | July 8, 2014 |  2
My patient was a 69 year old lady with metastatic small cell lung cancer. She was on experimental chemotherapy and was admitted from clinic with worsening lower extremity edema and a new oxygen requirement.  She underwent a chest and abdominal CT that revealed new pulmonary masses, tumor and a mass invading her right pulmonary artery, […]
By  | June 2, 2013 |  0
The large multi-center ICU trial randomized ICUs to 1 of 3 strategies: MRSA screening/isolation, MRSA screening/isolation/decolonization, or global decolonization (5 days BID nasal mupiricin and daily chlorhexidine bathing). The hazard ratios for MRSA isolates in the 3 groups were 0.92, 0.75, 0.63 respectively. The hazard ratios for any bloodstream infection in the 3 groups were […]
By  | May 25, 2013 |  0
This trial found no difference in patient outcomes (mortality or LOS) if admitted during a time of 24/7 intensivist coverage, or during a time with only daytime intensivist coverage (with home call at night) in a medical ICU. This study does not show a patient benefit to a 24/7 intensivist staffing model in an academic […]